The effect of Vit-D on adiponectin plasma levels and insulin resistance in first-degree relatives of diabetic patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201105176430N1

Enrollment

Registered

2011-07-26

Start date

2010-04-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

First degree Relatives of Diabetic Patients. Diabetes mellitus

Interventions

Intervention 1: Intervention group will cosume 50000 IU Vit D weekly for 12 weeks. Intervention 2: Control group will receive nothing.

Treatment - Drugs

Intervention group will cosume 50000 IU Vit D weekly for 12 weeks

Control group will receive nothing

Eligibility

Sex/Gender

All

Age

25 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: First-degree relatives of diabetic patients; BMI >25kg/m2; age between 25-65 years. Exclusion criteria: Diabetic patients; who has consumed Vit-D supplementation or Metformin for past three months.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Insulin. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Insulin Kit and the Unit is mu/lit.;Adiponectin. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Adiponectin kit and the unit is ng/ml.	—

Secondary

Measure	Time frame
FBS. Timepoint: 12 weeks. Method of measurement: Measurement of blood glucose by Auto analyzer method.;2hpp. Timepoint: 12 weeks. Method of measurement: Measurement of blood glucose by Auto analyzer method.;TG. Timepoint: 12 weeks. Method of measurement: Measurement of triglyceride by Auto Analyzer method.;Cholesterol. Timepoint: 12 weeks. Method of measurement: Measurement of cholestrol by Auto nalyser method.;HDL. Timepoint: 12 weeks. Method of measurement: Measurement of HDL by Auto Analyser method.;LDL. Timepoint: 12 weeks. Method of measurement: Measurement of LDL by Auto Analyser method.	—

Measure

Time frame

FBS. Timepoint: 12 weeks. Method of measurement: Measurement of blood glucose by Auto analyzer method.;2hpp. Timepoint: 12 weeks. Method of measurement: Measurement of blood glucose by Auto analyzer method.;TG. Timepoint: 12 weeks. Method of measurement: Measurement of triglyceride by Auto Analyzer method.;Cholesterol. Timepoint: 12 weeks. Method of measurement: Measurement of cholestrol by Auto nalyser method.;HDL. Timepoint: 12 weeks. Method of measurement: Measurement of HDL by Auto Analyser method.;LDL. Timepoint: 12 weeks. Method of measurement: Measurement of LDL by Auto Analyser method.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Ahmad Eghbali zarch

Yazd Diabetes Research Center, Shahid Sadooghi University of Medical Sciences

drc@ssu.ac.ir+98 35 1522 3999

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026